Hepatic Oncology最新文献_第2页

Uncooled TATO microwave system for liver ablation. 用于肝脏消融的非冷却式TATO微波系统。

IF 5

Hepatic Oncology Pub Date : 2022-12-01 DOI: 10.2217/hep-2022-0002

Eduardo Crespo, Antonio Hermosín, Álvaro Villalba, Eduardo Daguer, José Flores, Javier Periañez, Mario Martínez-Galdámez, Ernesto Santos

引用次数: 0

Management of hepatocellular carcinoma from diagnosis in routine clinical practice. 从临床常规诊断看肝癌的处理。

IF 5

Hepatic Oncology Pub Date : 2022-12-01 DOI: 10.2217/hep-2021-0011

Tasneem Lokhandwala, Abdalla Aly, Eileen Farrelly, Joanne P Willey, Lois E Lamerato, Marcus Healey, Anna D Coutinho, Brian S Seal

引用次数: 0

Pathological complete response with immunotherapy and brachytherapy to 15 metastatic liver lesions in a single patient. 病理完全反应与免疫治疗和近距离治疗15转移性肝病变在一个病人。

IF 5

Hepatic Oncology Pub Date : 2022-09-27 eCollection Date: 2022-09-01 DOI: 10.2217/hep-2021-0014

Gokula Kumar Appalanaido, Muhamad Zabidi Ahmad, Syadwa Abdul Shukor, Alex Khoo Cheen Hoe, Manisekar K Subramaniam, Ang Soo Fan, Mohd Zahri Abdul Aziz

{"title":"Pathological complete response with immunotherapy and brachytherapy to 15 metastatic liver lesions in a single patient.","authors":"Gokula Kumar Appalanaido, Muhamad Zabidi Ahmad, Syadwa Abdul Shukor, Alex Khoo Cheen Hoe, Manisekar K Subramaniam, Ang Soo Fan, Mohd Zahri Abdul Aziz","doi":"10.2217/hep-2021-0014","DOIUrl":"https://doi.org/10.2217/hep-2021-0014","url":null,"abstract":"Materials & methods: High dose rate interstitial brachytherapy (HDR-IBT) treatment plan for 15 metastatic liver lesions in a patient with pancreatic cancer was retrieved and analyzed for liver dose parameters and diaphragm dose. Serial 18F-FDG PET-CT scans were reviewed for disease response assessment and left liver lobe volume. Serial laboratory records were analyzed for liver parameters.Results: Left liver lobe volume increased from 241 cm3 pre-HDR-IBT to estimated 600 cm3 after seven sessions of HDR-IBT. Metabolic complete response (CR) and subsequently pathological CR was confirmed in the right hepatotectomy specimen for all the 15 PET-CT avid lesions treated with HDR-IBT. Maximum diaphragm dose in a single fraction was 82 Gy. The liver parameters were stable and patient did not develop radiation induced liver disease.Discussion: This is the largest reported series of HDR-IBT to liver lesions in a single patient. This first ever reported combined treatment of immunotherapy (IT) and HDR-IBT had likely rendered this patient disease free both at local the liver and systemically. Metabolic CR by PET-CT can be seen as early as 46 days after HDR-IBT. Diaphragm can tolerate very high doses of radiation and repeated treatment.Conclusion: In this patient HDR-IBT for multiple liver lesions with IT is well tolerated. PET-CT can be used for response assessment of HDR-IBT liver. Synergistic effect of IT with HDR-IBT and it's role as bridging for liver resection has clinical potential and should be further studied in prospective trials.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"9 3","pages":"HEP44"},"PeriodicalIF":5.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/73/hep-09-44.PMC9517960.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40383805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma. β受体阻滞剂对不可切除肝细胞癌患者生存结局的影响。

IF 5

Hepatic Oncology Pub Date : 2022-04-01 DOI: 10.2217/hep-2021-0010

Ellery Altshuler, Mahmoud Aryan, Govind Kallumkal, Hanzhi Gao, Jake Wilson, Ahmed Ouni, Edward De Leo, Wissam Hanayneh, Kelsey Pan

{"title":"Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma.","authors":"Ellery Altshuler, Mahmoud Aryan, Govind Kallumkal, Hanzhi Gao, Jake Wilson, Ahmed Ouni, Edward De Leo, Wissam Hanayneh, Kelsey Pan","doi":"10.2217/hep-2021-0010","DOIUrl":"https://doi.org/10.2217/hep-2021-0010","url":null,"abstract":"Background: β-blockers (BBs) have shown promise in improving overall survival (OS) in patients with breast, ovarian, pancreatic and lung cancer. However, few studies have evaluated the impact of BBs on unresectable hepatocellular carcinoma (HCC). Methods: The authors compared clinical data and outcomes between unresectable HCC patients based on whether they were prescribed BBs. Results: There was significantly decreased disease progression in the BB group compared with the non-BB group (22.8 vs 28.0%; p < 0.05). No difference was seen in OS or progression-free survival between groups. Those specifically on selective BBs had improved OS (hazard ratio: 0.75; 95% CI: 0.61–0.94; p = 0.01) and progression-free survival (hazard ratio: 0.66; 95% CI: 0.45–0.96; p = 0.03) compared with non-BB patients. Conclusion: Although the authors' study did not demonstrate that BBs improve OS in HCC, it did show decreased disease progression among patients with HCC who were taking BBs compared with those who were not.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"9 2","pages":"HEP43"},"PeriodicalIF":5.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/75/hep-09-43.PMC9136628.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10601607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Portal vein embolization: rationale, techniques, outcomes and novel strategies. 门静脉栓塞:原理、技术、结果和新策略。

IF 5

Hepatic Oncology Pub Date : 2021-09-21 eCollection Date: 2021-12-01 DOI: 10.2217/hep-2021-0006

Jirapa Chansangrat, Nattawut Keeratibharat

引用次数: 10

Imaging of chemotherapy-induced liver toxicity: an illustrated overview. 化疗引起的肝毒性的影像学:图解概述。

IF 5

Hepatic Oncology Pub Date : 2021-09-15 eCollection Date: 2021-12-01 DOI: 10.2217/hep-2020-0026

Giovanni Brondani Torri, Matheus Dorigatti Soldatelli, Gustavo Felipe Luersen, Caroline Lorenzoni Almeida Ghezzi

引用次数: 2

Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. 肝细胞癌推荐系统治疗试验的系统文献综述。

IF 1.2

Hepatic Oncology Pub Date : 2021-08-26 eCollection Date: 2022-03-01 DOI: 10.2217/hep-2021-0003

Sarah Ronnebaum, Abdalla Aly, Dipen Patel, Fernando Benavente, Juan-David Rueda

引用次数: 0

Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma. 早期小肝癌和进展性肝癌肿瘤突变负荷的评价。

IF 5

Hepatic Oncology Pub Date : 2021-08-03 eCollection Date: 2021-12-01 DOI: 10.2217/hep-2020-0034

Mary Wong, Jong T Kim, Brian Cox, Brent K Larson, Stacey Kim, Kevin M Waters, Eric Vail, Maha Guindi

{"title":"Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma.","authors":"Mary Wong, Jong T Kim, Brian Cox, Brent K Larson, Stacey Kim, Kevin M Waters, Eric Vail, Maha Guindi","doi":"10.2217/hep-2020-0034","DOIUrl":"https://doi.org/10.2217/hep-2020-0034","url":null,"abstract":"While researchers know that tumor mutational burden (TMB) is low in hepatocellular carcinoma (HCC), prior studies have not investigated TMB in cirrhosis, small early HCC and progressed HCC. HCC (n = 18) and cirrhosis (n = 6) cases were identified. TMB was determined by a 1.7 megabase, 409-gene next-generation sequencing panel. TMB values were defined as the number of nonsynonymous variants per megabase of sequence. There was no significant difference between cirrhosis versus small early HCC or between cohorts when stratified by size, early versus progressed, differentiation or morphology. There was a significant difference between cirrhosis and small early HCC versus progressed HCC (p = 0.045), suggesting TMB may be related to HCC progression. TMB similarities in small early HCC and background cirrhosis suggest TMB is not a useful tool for diagnosing small early HCC. Additional study is needed to address TMB in histological and molecular subsets of HCC.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 4","pages":"HEP39"},"PeriodicalIF":5.0,"publicationDate":"2021-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c5/fb/hep-08-39.PMC8577511.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39701720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases. 经动脉化疗栓塞单独或随后贝伐单抗治疗结肠直肠癌肝转移。

IF 5

Hepatic Oncology Pub Date : 2021-07-13 eCollection Date: 2022-03-01 DOI: 10.2217/hep-2020-0031

Giammaria Fiorentini, Donatella Sarti, Michele Nardella, Riccardo Inchingolo, Massimiliano Nestola, Alberto Rebonato, Caterina Fiorentini, Camillo Aliberti, Roberto Nani, Stefano Guadagni

{"title":"Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases.","authors":"Giammaria Fiorentini, Donatella Sarti, Michele Nardella, Riccardo Inchingolo, Massimiliano Nestola, Alberto Rebonato, Caterina Fiorentini, Camillo Aliberti, Roberto Nani, Stefano Guadagni","doi":"10.2217/hep-2020-0031","DOIUrl":"10.2217/hep-2020-0031","url":null,"abstract":"Aims: Bevacizumab (B) in association with systemic chemotherapy is commonly used for the treatment of colorectal cancer liver metastases. The aim of this study was to monitor tumor response, overall survival (OS) and progression-free survival (PFS) of patients with colorectal cancer liver metastases treated with transarterial chemoembolization (TACE) + B compared with TACE alone and to correlate the results with KRAS mutational status.Patients & methods: This was an observational multicentric case-control study (NCT03732235) on the efficacy and safety of B administered after TACE.Results: The disease control rate was significantly higher for the TACE + B than the TACE alone group (p < 0.001). KRAS wild-type patients had a significantly better disease control rate than those with KRAS mutations in the TACE + B group. Median OS and PFS were similar for the TACE + B and TACE groups, whereas median time to progression was significantly higher for the TACE + B group (p < 0.01).Conclusion: The combination of TACE with B may improve tumor response and delay disease progression.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"9 1","pages":"HEP40"},"PeriodicalIF":5.0,"publicationDate":"2021-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/dd/hep-09-40.PMC8577510.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39701722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience. 阿霉素洗脱聚乙二醇微球治疗不可切除的肝细胞癌:单中心经验。

IF 5

Hepatic Oncology Pub Date : 2021-06-04 eCollection Date: 2021-09-01 DOI: 10.2217/hep-2020-0035

Gerardo Tovar-Felice, Andrés García-Gámez, Virgilio Benito-Santamaría, David Balaguer-Paniagua, Jordi Villalba-Auñón, Jaume Sampere-Moragues

{"title":"Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience.","authors":"Gerardo Tovar-Felice, Andrés García-Gámez, Virgilio Benito-Santamaría, David Balaguer-Paniagua, Jordi Villalba-Auñón, Jaume Sampere-Moragues","doi":"10.2217/hep-2020-0035","DOIUrl":"https://doi.org/10.2217/hep-2020-0035","url":null,"abstract":"Background: Transarterial chemoembolization (TACE) is indicated for unresectable hepatocellular carcinoma.Methods: This was a retrospective study of 50 hepatocellular carcinoma patients treated with TACE using doxorubicin-loaded LifePearl™ to investigate the safety and efficacy of TACE.Results: There was no 30-day mortality, and limited adverse events were reported. At best tumor response, complete response and disease control were 58% and 94%, respectively, with a median of 4.5 months of follow-up. Median overall survival was 33.8 months. Patients with Barcelona Clinic Liver Cancer stage 0 and stage A at best tumor response showed a higher complete response rate (83%) than patients with Barcelona Clinic Liver Cancer stage B (complete response: 50%; p = 0.0414).Conclusion: Doxorubicin-loaded LifePearl™ TACE might be an effective treatment, with a good safety profile, for patients with early/intermediate-stage hepatocellular carcinoma. Further prospective data, especially with a small cohort of selected patients, are required to confirm these results.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 3","pages":"HEP38"},"PeriodicalIF":5.0,"publicationDate":"2021-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/44/5b/hep-08-38.PMC8369521.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39336544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3